Royalty Pharma PLC $RPRX Shares Sold by AlTi Global Inc.

AlTi Global Inc. reduced its position in Royalty Pharma PLC (NASDAQ:RPRX) by 21.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 70,402 shares of the biopharmaceutical company’s stock after selling 19,544 shares during the quarter. AlTi Global Inc.’s holdings in Royalty Pharma were worth $2,484,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RPRX. Smartleaf Asset Management LLC increased its holdings in Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. Financial Consulate Inc. purchased a new position in Royalty Pharma in the 3rd quarter valued at about $35,000. Richardson Financial Services Inc. purchased a new stake in shares of Royalty Pharma during the third quarter worth about $54,000. Farther Finance Advisors LLC raised its position in shares of Royalty Pharma by 44.3% in the third quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 632 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in shares of Royalty Pharma by 389.8% during the third quarter. Versant Capital Management Inc now owns 2,586 shares of the biopharmaceutical company’s stock valued at $91,000 after buying an additional 2,058 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Buying and Selling at Royalty Pharma

In related news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $41.09, for a total value of $821,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Terrance P. Coyne sold 20,163 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $43.29, for a total value of $872,856.27. Following the completion of the sale, the chief financial officer owned 22,885 shares of the company’s stock, valued at $990,691.65. This trade represents a 46.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,309,216 shares of company stock worth $52,015,364 over the last ninety days. 18.90% of the stock is currently owned by corporate insiders.

Royalty Pharma Stock Up 0.4%

Shares of NASDAQ RPRX opened at $44.21 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $44.92. The stock’s 50-day simple moving average is $40.09 and its 200-day simple moving average is $38.12. The firm has a market cap of $25.52 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 1.68 and a beta of 0.42.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be paid a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. Royalty Pharma’s payout ratio is presently 66.67%.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday, January 22nd. UBS Group upgraded shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Friday, January 30th. Citigroup boosted their price target on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Leerink Partners set a $45.00 target price on Royalty Pharma in a report on Thursday, December 11th. Finally, Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Royalty Pharma has an average rating of “Moderate Buy” and a consensus target price of $47.50.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.